I agree that our potential is staggering in multiple revenue streams. I also believe it is a fair statement to say at this point in time that B appears to be a winner in all areas tested to date and most likely the dermatological applications will also follow suit. I think the dermatology related revenues could be on a par w/ OM, Psoriasis, and ABSSSI combined while IBD is very large and I have no current clue as to overall yearly potential.

Some may disagree, but IMO P results due out soon is pretty much a lock for excellent effectiveness and safety.

All in all, things couldn't be better though the FUDsters would lead one to believe everything going to hell in a hand basket. I really feel sorry for those that only know the other board as an IPIX news source since they get dismal predictions 24/7.

Does seem to be rubbing the FUDsters raw that Leo apparently has chosen not to put out any news on the unblinding of P data.